Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Catalent Pharma Names New CTO, SVP
Dr Nielsen most recently served as executive vice president of pharmaceuticals for URLMutual Pharmaceutical, where he lead new product development and licensing activities for both products and drug
Dr Nielsen most recently served as executive vice president of pharmaceuticals for URLMutual Pharmaceutical, where he lead new product development and licensing activities for both products and drug
A total of 401 patients participated in the 12-week, double-blind, placebo-controlled study, designed to assess the efficacy of duloxetine 60mg once daily on the reduction of pain severity
The company said that the patent, which will remain in force until 2028, covers a new Repligen proprietary product which is now available in commercial quantities. The product
In the study, 200 healthy human volunteers took a once daily dose of oral interferon or placebo for 16 weeks during the Australian cold and flu season. There
Labopharm expects Oleptro to be available for prescription in the US later this year, with specific timing for its launch to be determined within the context of the
The study indicates that in animals treated with PLX cells, there were differences to the control groups in the following parameters: improvement in sensory and motor deficits, reduction
The company said that the patent issuance opens the door for sales and distribution into Mexico, and is expected to accelerate HealthSport’s move into the international marketplace. The
The company said that the Phase 3 X-PECT (Xeloda + Perifosine Evaluation in Colorectal cancer Treatment) trial will be a randomised (1:1), double-blind trial comparing the efficacy and
The company said that its scientists are currently presenting the validation results of the SmartChip Real-Time PCR System at the Cambridge Healthcare Institute’s 17th International Molecular Medicine Tri-Conference.
The company said that the approval was based on the clinical studies which showed that the addition of lidocaine to Restylane and Perlane reduced pain experienced by patients,